Literature DB >> 23338845

Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis.

Zhijian Pan1, Chunzhou Chen, Haocheng Long, Changjiang Lei, Gang Tang, Lei Li, Jiarui Feng, Feixiang Chen.   

Abstract

Glypican‑3 (GPC3) is a membrane heparan sulfate proteoglycan involved in cell proliferation, differentiation, adhesion, migration and the development of the majority of mesodermal tissues and organs. GPC3 has been found to be important for the occurrence and development of hepatocellular carcinoma (HCC). Therefore, it may be suitable for use as a novel molecular marker for the diagnosis of primary liver cancer. In the present study, the role of GPC3 in the occurrence and development of HCC was determined. GPC3 recombinant vector was transfected into two HCC cell lines, Huh7 and SK‑HEP‑1, to upregulate the expression of GPC3 and examine changes in the biological behavior of the cells. Results indicate that overexpression of GPC3 in Huh7 and SK‑HEP‑1 cells effectively inhibited cell proliferation and cell invasion through induction of apoptosis. However, cotreatment of the cells with insulin‑like growth factor 2 (IGF2) and fibroblast growth factor 2 (FGF2) was found by Annexin V‑PI flow cytometric analysis to significantly inhibit the apoptotic cell death induced by GPC3 overexpression. These observations indicate that GPC3 may act as a negative regulator of IGF2 and FGF2 pathways. Taken together, these results demonstrate that overexpression of GPC3 inhibits the occurrence and development of HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23338845     DOI: 10.3892/mmr.2013.1279

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

1.  [Value of detection of serum glypican-3 level in diagnosis and therapeutic effect evaluation of primary hepatocellular carcinoma].

Authors:  Yuan-Yuan Wang; Chen-Jie Zhou; Jing Li; Ling Zhou; Ming-Song Li; Bing Xiao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

2.  Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.

Authors:  Ying Liu; Dongping Zheng; Mingming Liu; Jiao Bai; Xi Zhou; Baolan Gong; Jieyu Lü; Yi Zhang; Hui Huang; Wenying Luo; Guangrong Huang
Journal:  Tumour Biol       Date:  2015-05-14

Review 3.  Recent advances in hepatocellular carcinoma therapy.

Authors:  Rinku Dutta; Ram I Mahato
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

4.  Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.

Authors:  Xiaoxiao Jin; Xiaotao Liu; Zining Zhou; Yan Ding; Yandan Wu; Jie Qiu; Chuanlai Shen
Journal:  Cancer Immunol Immunother       Date:  2021-11-01       Impact factor: 6.968

5.  Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma.

Authors:  Weiqing Luo; Zhigang Ren; Sheng Gao; Hailong Jin; Geer Zhang; Lin Zhou; Shusen Zheng
Journal:  Oncol Lett       Date:  2016-01-07       Impact factor: 2.967

Review 6.  Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis.

Authors:  Hong Liu; Chunmei Yang; Wenzhu Lu; Yong Zeng
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

7.  Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma.

Authors:  Fuqiang Yin; Lipei Shu; Xia Liu; Ting Li; Tao Peng; Yueli Nan; Shu Li; Xiaoyun Zeng; Xiaoqiang Qiu
Journal:  J Exp Clin Cancer Res       Date:  2016-08-27

Review 8.  Can glypican-3 be a disease-specific biomarker?

Authors:  Chaolei Chen; Xiaomin Huang; Zhaojian Ying; Dengmin Wu; Yani Yu; Xiangdong Wang; Chengshui Chen
Journal:  Clin Transl Med       Date:  2017-05-16

9.  Elevated GPC3 level promotes cell proliferation in liver cancer.

Authors:  Shanshan Wang; Ning Chen; Yuhan Chen; Lin Sun; Li Li; Hui Liu
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.